Kiniksa PharmaceuticalsKNSA
13F holders, Q1 2026 (March 31)2holders +1
1new positions
0sold out
$48.18avg. 13F price*
At the end of Q1 2026, 2 institutions reported holding Kiniksa Pharmaceuticals Ltd. (KNSA) in their 13F filings, up 1 from Q4 2025. 1 opened new positions and 0 sold out. The largest holders were Harbor Capital Advisors, Inc. ($726K) and Uniplan Investment Counsel, Inc. ($24K).
- Company
- Kiniksa Pharmaceuticals Ltd.
- CUSIP
- G5269C101
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $24K |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 493 shares bought and 6,475 shares sold, net −5,982 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Harbor Capital Advisors, Inc. | 0.06% | Reduce -30.1% | 15,068 | $726K |
| Uniplan Investment Counsel, Inc. | 0.00% | New | 493 | $24K |
"% of holder's portfolio" is KNSA's weight in each manager's 13F, not the share of Kiniksa Pharmaceuticals Ltd. the manager owns.